30991-42-5

Basic information

• Product Name: 2-HYDROXY-3-METHYLBENZHYDRAZIDE
• Synonyms: 2-Hydroxy-3-methylbenzohydrazide;3-METHYLSALICYLHYDRAZIDE;2-HYDROXY-3-METHYLBENZHYDRAZIDE;O-CRESOTIC HYDRAZIDE;TIMTEC-BB SBB007676;2-hydroxy-3-methylbenzohydrazide(SALTDATA: FREE)
• CAS NO: 30991-42-5
• Molecular Formula: C₈H₁₀N₂O₂
• Molecular Weight: 166.18
• EINECS: -0
• Product Categories: Aromatic Hydrazides, Hydrazines, Hydrazones and Oximes
• Mol File: 30991-42-5.mol
• Article Data: 3

Chemical Properties

• Melting Point: 190-191°C
• Appearance: /
• Density: 1.262 g/cm³
• Refractive Index: 1.607
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 8.78±0.35(Predicted)
• BRN: 2639905
• CAS DataBase Reference: 2-HYDROXY-3-METHYLBENZHYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-HYDROXY-3-METHYLBENZHYDRAZIDE(30991-42-5)
• EPA Substance Registry System: 2-HYDROXY-3-METHYLBENZHYDRAZIDE(30991-42-5)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• HazardClass: IRRITANT
• Hazardous Substances Data: 30991-42-5(Hazardous Substances Data)

Usage

General Description

2-HYDROXY-3-METHYLBENZHYDRAZIDE is a chemical compound with the molecular formula C8H10N2O2. It is also known as 5-methyl-2-(2-hydroxyphenyl)hydrazinecarboxamide and is commonly used as a pharmaceutical intermediate. It has been found to have potential anti-tuberculosis activity and is being studied for its potential use in the treatment of tuberculosis. Additionally, it has been investigated for its potential antioxidant and anti-inflammatory properties. 2-HYDROXY-3-METHYLBENZHYDRAZIDE is a yellow solid with a melting point range of 213-217°C and is soluble in various organic solvents.

InChI:InChI=1/C8H10N2O2/c1-5-3-2-4-6(7(5)11)8(12)10-9/h2-4,11H,9H2,1H3,(H,10,12)

Upstream product

• 83-40-9 3-methylsalicylic acid 
• 55211-85-3 ethyl 2-hydroxy-3-methylbenzoate 
• 23287-26-5 3-methylsalicylic acid methyl ester 

Downstream Products

• 1429183-43-6 2-Methyl-6-(5-((2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl)thio)-1,3,4-oxadiazol-2-yl)phenol 
• 1429183-55-0 6-(5-thio-1,3,4-oxadiazol-2-yl)-2-methylphenol 
• 394695-74-0 N'-(2-hydroxy-3-methoxybenzylidene)-2-hydroxy-3-methylbenzohydrazide 
• 1338733-48-4 N'-(3,5-dibromo-2-hydroxybenzylidene)-2-hydroxy-3-methylbenzohydrazide 
• 1349180-96-6 N'-(3,5-dichloro-2-hydroxybenzylidene)-2-hydroxy-3-methylbenzohydrazide 
• 2639-41-0 6,6'-(1,3,4-oxadiazole-2,5-diyl)bis(2-methylphenol) 
• 95060-13-2 2-Hydroxy-3-methyl-benzoic acid [2-oxo-1,2-dihydro-indol-(3Z)-ylidene]-hydrazide 

Relevant articles and documents

Relationship between the structure of newly synthesized derivatives of 1,3,4-oxadiazole containing 2-methylphenol and their antioxidant and antibacterial activities

1,3,4-oxadiazole-5-thion ring(2) successfully formed at position six of 2-methylphenol and five of their thioalkyl(3a-e). Furthermore 6-(5-(Aryl)-1,3,4-oxadiazol-2-yl)-2-methylphenol (5a-i) were formed at position six by two method. The first method was f

Novel 1,3,4-oxadiazole thioether derivatives targeting thymidylate synthase as dual anticancer/antimicrobial agents

A series of novel 1,3,4-oxadiazole thioether derivatives (compounds 9-44) were designed and synthesized as potential inhibitors of thymidylate synthase (TS) and as anticancer agents. The in vitro anticancer activities of these compounds were evaluated against three cancer cell lines by the MTT method. Among all the designed compounds, compound 18 bearing a nitro substituent exhibited more potent in vitro anticancer activities with IC50 values of 0.7 ± 0.2, 30.0 ± 1.2, 18.3 ± 1.4 μM, respectively, which was superior to the positive control. In the further study, it was identified as the most potent inhibitor against two kinds of TS protein (for human TS and Escherichia coli TS, IC50 values: 0.62 and 0.47 μM, respectively) in the TS inhibition assay in vitro and the most potent antibacterial agents with MIC (minimum inhibitory concentrations) of 1.56-3.13 μg/mL against the tested four bacterial strains. Molecular docking and 3D-QSAR study supported that compound 18 can be selected as dual antitumor/antibacterial candidate in the future study.